Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML

Cancer Science

Volumn 100, Issue 6, 2009, Pages 1128-1136

  Kojima, Kensuke ^a   Shimanuki, Masaya ^a   Shikami, Masato ^b   Andreeff, Michael ^c   Nakakuma, Hideki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 1 INHIBITOR; DOXORUBICIN; NUTLIN 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RO 3306; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; CELL CYCLE; CELL STRAIN HL 60; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-MDM2; QUINOLINES; RNA, SMALL INTERFERING; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67649863759     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01150.x     Document Type: Article

References (45)

1. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005, 30:630-41.
2. Santamaría D, Barrière C, Cerqueira A. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007, 448:811-15.
3. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24:1770-83.
4. de Cárcer G, de Castro IP, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007, 14:969-85.
5. Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 2005, 7:831-6.
6. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007, 13:820-7.
7. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003, 63:230-5.
8. Pennati M, Campbell AJ, Curto M. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther 2005, 4:1328-37.
9. Vassilev LT, Tovar C, Chen S. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA 2006, 103:10 660-5.
10. Faderl S, Kantarjian HM, Estey E. The prognostic significance of p16 (INK4a)/p14 (ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000, 89:1976-82.
11. Kornblau SM, Womble M, Qiu YH. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108:2358-65.
12. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci USA 2004, 101:17 456-61.
13. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M. MEK inhibition enhances nuclear proapoptotic function of p53 in AML cells. Cancer Res 2007, 67:3210-19.
14. Secchiero P, Zerbinati C, di Iasio MG. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007, 8:395-403.
15. Vassilev LT, Vu BT, Graves B. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-8.
16. Kojima K, Konopleva M, Samudio IJ. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005, 106:3150-9.
17. Kojima K, Shimanuki M, Shikami M. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008, 22:1728-36.
18. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in AML. Blood 2008, 112:2886-95.
19. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-49.
20. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005, 106:2513-19.
21. Alvi AJ, Austen B, Weston VJ. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005, 105:4484-91.
22. Saddler C, Ouillette P, Kujawski L. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008, 111:1584-93.
23. Secchiero P, Barbarotto E, Tiribelli M. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107:4122-9.
24. Coll-Mulet L, Iglesias-Serret D, Santidrián AF. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006, 107:4109-14.
25. Stühmer T, Chatterjee M, Hildebrandt M. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005, 106:3609-17.
26. Shangary S, Qin D, McEachern D. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008, 105:3933-8.
27. Byrd JC, Lin TS, Dalton JT. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399-404.
28. Tibes R, Jimeno A, Von Hoff DD. Phase I dose escalation study of the oral multi-CDK inhibitor PHA-848125. J Clin Oncol 2008, 26:160s.
29. Mahadevan D, Plummer R, Squires MS. A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. J Clin Oncol 2008, 26:161s.
30. Bayart E, Grigorieva O, Leibovitch S, Onclercq-Delic R, Amor-Guéret M. A major role for mitotic CDC2 kinase inactivation in the establishment of the mitotic DNA damage checkpoint. Cancer Res 2004, 64:8954-9.
31. Mayer F, Mueller S, Malenke E, Kuczyk M, Hartmann JT, Bokemeyer C. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs 2005, 23:205-11.
32. Castedo M, Perfettini J-L, Roumier T. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002, 9:1287-93.
33. Golsteyn RM. Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle. Cancer Lett 2005, 217:129-38.
34. Yuan Z, Becker EB, Merlo P. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 2008, 319:1665-8.
35. Liu P, Kao TP, Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene 2008, 27:4733-44.
36. Allan LA, Clarke PR. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol Cell 2007, 26:301-10.
37. Hahntow IN, Schneller F, Oelsner M. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004, 18:747-55.
38. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001, 20:240-51.
39. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277:3247-57.
40. O'Connor DS, Grossman D, Plescia J. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000, 97:13 103-7.
41. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000, 113:4363-71.
42. De la Cueva E, García-Cao I, Herranz M. Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene 2006, 25:4128-32.
43. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 2006, 5:2778-86.
44. Xu SQ, El-Deiry WS. p21WAF1/CIP1 inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 2000, 269:179-90.
45. Steinman RA, Johnson DE. p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Mol Med 2000, 6:736-49.